News

June St. Jude Medical Inc. announced preliminary results from the EnligHTN III study, which found the company’s second-generation EnligHTN renal denervation system provided safe and effective...

Alere announced a class I recall of its INRatio2 PT/INR professional test strips, part of the Alere lNRatio2 PT/INR monitoring system (professional use) which also consists of the INRatio2 monitor...

Hospira Inc. issued a nationwide recall to the user level for one lot of Dobutamine Injection, USP, 250 mg, 20 mL, single-dose fliptop vial, (NDC 0409-2344-02), Lot 27-352-DK. (NDC and lot number...

Journal of Endovascular Therapy Hypertension Renal Denervation Therapy

Patients with hypertension after renal artery stenting who do not respond to drug treatment may have another option. 

Power Plate Whole Body Vibration Blood Pressure Florida State University

Six independent studies published within the past 10 years have shown a link between whole body vibration and lowered blood pressure.

The National Lipid Assn. (NLA) released a draft summary that highlights key aspects of care that provide a thorough supplement and direction for clinicians treating patients with dyslipidemia.

New data presented for the first time at the World Heart Federation’s World Congress of Cardiology 2014 shows a significant improvement in both patient adherence and risk factor control when...

May 6, 2014 — The National Lipid Association (NLA) recently convened an expert panel to examine various aspects of statin safety and statin tolerance. Results of the symposium findings...

April 29, 2014 — Armetheon Inc. announced it has reached agreement with the U.S. Food and Drug Administration (FDA) on a special protocol assessment (SPA) for the final pivotal trial of tecarfarin...

Cardiosonic Inc CE mark TIVUS ablative catheter renal denervation hypertension

Cardiosonic Ltd. announced CE marking of its TIVUS (therapeutic intravascular ultrasound) ablative catheter device.

April 21, 2014 — Decision Resources Group announced in a report that Servier's ivabradine (procoralan) is set to become the clinical gold standard in the treatment of chronic heart failure (...

April 10, 2014 — The 2014 Guideline for the Management of Patients With Atrial Fibrillation includes recommendations for an increased use of radio frequency (RF) ablation in the treatment of non-...

LipoScience Inc. announced data showing that patients managed to a target LDL particle (LDL-P) number, as measured by LipoScience's NMR LipoProfile test, achieved a 22 to 25 percent greater...

In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary...

April 7, 2014 — Strategies aimed at reducing the number of patients with heart failure and other cardiovascular conditions who find themselves back in the hospital after discharge were identified...

Medtronic, SYMPLICITY, SYMPLICITY HTN-3 trial, renal denervation, ACC.14

A major disappointment earlier this year was the announcement by Medtronic that its renal denervation system failed to meet its primary endpoint for efficacy in the U.S. SYMPLICITY HTN-3 trial....

Statins are associated with a significant improvement in erectile function, a fact researchers hope will encourage men who need statins to reduce their risk of heart attack to take them, according...

CBSET Renal Denervation Hypertension Therapies Symplicity-3 Trial

Scientists at CBSET are reminding thought leaders in renal denervation that there is a seminal experimental and computational template for the more rational, comprehensive preclinical evaluation...

statins, heart scan, CT scan

As long as inexpensive statins, which lower cholesterol, are readily available and patients do not mind taking them, it does not make sense to do a heart comuted tomography (CT) scan to measure...

Patient enrollment has been completed four months ahead of plan in the Phase III clinical trial EUCLID study for AstraZeneca's ticagrelor (Brilinta) tablets. Part of PARTHENON,...